Other languages BriaCell Therapeutics Corp. Nasdaq

Equities

BCTX

CA1079301091

Market Closed - Nasdaq Other stock markets 02:00:00 06/07/2024 am IST			5-day change	1st Jan Change
1.01 ^USD	+1.00%		-11.40%	-82.74%

14/06	BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024	CI
03/06	Briacell Therapeutics Corp. Presents Clinical Efficacy Data At ASCO 2024	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024	15/06
Briacell Therapeutics Corp. Presents Clinical Efficacy Data At ASCO 2024	03/06
BriaCell Therapeutics Corp. Initiates Patient Enrollment in First-In-Human Study of Bria-Ots in Advanced Metastatic Breast Cancer	30/05
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study	28/05
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments	28/05
BriaCell Therapeutics Corp. Announces Clinical Supply Agreement with BeiGene, Ltd. for Bria-OTS First in Human Study	28/05
Briacell Therapeutics Insider Bought Shares Worth $2,000,001, According to a Recent SEC Filing	21/05
BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble	15/05
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+? and Bria-PROS+? Clinical Candidates for Breast and Prostate Cancer	10/04
BriaCell to Showcase Latest Bria-IMT Data in Poster Presentations at 2024 AACR	09/04
BriaCell Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	19/03
BriaCell to Present Clinical Data in CNS Metastasis and Antibody-Drug Conjugate Resistant Breast Cancer at AACR Conference	06/03
BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case	07/02
Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp Manufacturing	06/02
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with "Eye-Bulging" Metastatic Breast Cancer	04/01
BriaCell Has Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients	28/12
BriaCell Therapeutics Corp. Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients	28/12
BriaCell Therapeutics Corp. Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate Refractory Patient Subset	20/12
BriaCell Therapeutics Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023	15/12
BriaCell Highlights Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at Breast Cancer Symposium	06/12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BriaCell Therapeutics Corp. Nasdaq

Equities

BCTX

CA1079301091

Other languages

Filters